Understand the source comparison
VIP Side Effects Comparison — Dose-Dependent Profiles
The relationship between VIP dose and side effect incidence is linear and well-characterized. Understanding this relationship allows researchers to structure protocols that balance efficacy with tolerability. 50–100 mcg (low titration start) 5–8% 4–6% 2–4% 3–5
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The relationship between VIP dose and side effect incidence is linear and well-characterized. Understanding this relationship allows researchers to structure protocols that balance efficacy with tolerability.
- 50–100 mcg (low titration start)
- 5–8%
- 4–6%
- 2–4%
- 3–5%
- Minimal side effects; effective for dose introduction and tolerance assessment. Ideal starting range for VIP-naive subjects.
- 100–200 mcg (moderate therapeutic)
- 12–18%
- 10–15%
- 6–10%
- Moderate incidence; most effects are transient and resolve within 60 minutes. Standard maintenance range for most research applications.
- 200–400 mcg (high therapeutic)
- 22–28%
- 18–25%
- 10–14%
- Higher incidence but still predominantly mild. Appropriate for subjects who have completed 2–3 week titration and tolerate lower doses well.
- >400 mcg (exploratory/single-dose studies)
- 30–40%
- 25–35%
- 15–22%
- Side effects are expected and frequent. Reserved for single-dose experimental protocols; not suitable for sustained administration without medical oversight.